Benjamin Hohl - Net Worth and Insider Trading

Benjamin Hohl Net Worth

The estimated net worth of Benjamin Hohl is at least $0 dollars as of 2024-11-05. Benjamin Hohl is the CHIEF FINANCIAL OFFICER of Enliven Therapeutics Inc and owns about 0 shares of Enliven Therapeutics Inc (ELVN) stock worth over $0. Details can be seen in Benjamin Hohl's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Benjamin Hohl has not made any transactions after 2024-10-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Benjamin Hohl

To

Benjamin Hohl Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Benjamin Hohl owns 1 companies in total, including Enliven Therapeutics Inc (ELVN) .

Click here to see the complete history of Benjamin Hohl’s form 4 insider trades.

Insider Ownership Summary of Benjamin Hohl

Ticker Comapny Transaction Date Type of Owner
ELVN Enliven Therapeutics Inc 2024-10-07 Chief Financial Officer

Benjamin Hohl Latest Holdings Summary

Benjamin Hohl currently owns a total of 1 stock. Benjamin Hohl owns 0 shares of Enliven Therapeutics Inc (ELVN) as of October 28, 2024, with a value of $0.

Latest Holdings of Benjamin Hohl

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ELVN Enliven Therapeutics Inc 2024-10-28 0 27.70 0

Holding Weightings of Benjamin Hohl


Benjamin Hohl Form 4 Trading Tracker

According to the SEC Form 4 filings, Benjamin Hohl has made a total of 19 transactions in Enliven Therapeutics Inc (ELVN) over the past 5 years, including 0 buys and 19 sells. The most-recent trade in Enliven Therapeutics Inc is the sale of 6,250 shares on October 28, 2024, which brought Benjamin Hohl around $178,500.

Insider Trading History of Benjamin Hohl

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Benjamin Hohl Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Benjamin Hohl Ownership Network

Ownership Network List of Benjamin Hohl

No Data

Ownership Network Relation of Benjamin Hohl

Insider Network Chart

Benjamin Hohl Owned Company Details

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Benjamin Hohl is the Chief Financial Officer of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include director & President and CEO Samuel Kintz , director & Chief Scientific Officer Joseph P Lyssikatos , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Benjamin Hohl made 19 insider transaction in Enliven Therapeutics Inc (ELVN) with a net sale of 88,314. Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 240,342 shares made by Samuel Kintz , a net sale of 239,847 shares made by Joseph P Lyssikatos , and a net sale of 30,154 shares made by Richard A. Heyman .

In summary, during the past 3 months, insiders sold 183,359 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 183,359 shares. During the past 18 months, 4,855,709 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,855,709 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Enliven Therapeutics Inc Insider Transactions

No Available Data

Benjamin Hohl Mailing Address

Above is the net worth, insider trading, and ownership report for Benjamin Hohl. You might contact Benjamin Hohl via mailing address: 6200 Lookout Road, Boulder Co 80301.